Open access · CC-BY
via OpenAlex
The controversy of klotho as a potential biomarker in chronic kidney disease
Lixia Yu, Shasha Li, Min-Yue Sha, Jia-Wei Kong, Jianming Ye, Qifeng Liu
Frontiers in Pharmacology · 2022 · ▲ 37 citations
Abstract
Klotho is an identified longevity gene with beneficial pleiotropic effects on the kidney. Evidence shows that a decline in serum Klotho level occurs in early chronic kidney disease (CKD) and continues as CKD progresses. Klotho deficiency is associated with poor clinical outcomes and CKD mineral bone disorders (CKD-MBD). Klotho has been postulated as a candidate biomarker in the evaluation of CKD. However, the evidence for the clinical significance of the relationship between Klotho and kidney function, CKD stage, adverse kidney and/or non-kidney outcomes, and CKD-MBD remains inconsistent and in some areas, contradictory. Therefore, there is uncertainty as to whether Klotho is a potential biomarker in CKD; a general consensus regarding the clinical significance of Klotho in CKD has not been reached, and there is limited evidence synthesis in this area. To address this, we have systematically assessed the areas of controversy, focusing on the inconsistencies in the evidence base. We used a PICOM strategy to search for relevant studies and the Newcastle-Ottawa Scale scoring to evaluate included publications. We reviewed the inconsistent clinical findings based on the relationship of Klotho with CKD stage, kidney and/or non-kidney adverse outcomes, and CKD-MBD in human studies. Subsequently, we assessed the underlying sources of the controversies and highlighted future directions to resolve these inconsistencies and clarify whether Klotho has a role as a biomarker in clinical practice in CKD.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3389/fphar.2022.931746
- Canonical
- link ↗
- Fetched
- 2026-10-26 MST
Cite this
APA
Yu, L., Li, S., Sha, M., Kong, J., Ye, J., & Liu, Q. (2022). The controversy of klotho as a potential biomarker in chronic kidney disease. <em>Frontiers in Pharmacology</em>. https://doi.org/10.3389/fphar.2022.931746
Vancouver
Yu L, Li S, Sha M, Kong J, Ye J, Liu Q. The controversy of klotho as a potential biomarker in chronic kidney disease. Frontiers in Pharmacology. 2022. doi:10.3389/fphar.2022.931746.
BibTeX
@article{lixia2022Thecon,
title = {The controversy of klotho as a potential biomarker in chronic kidney disease},
author = {Lixia Yu and Shasha Li and Min-Yue Sha and Jia-Wei Kong and Jianming Ye and Qifeng Liu},
journal = {Frontiers in Pharmacology},
year = {2022},
doi = {10.3389/fphar.2022.931746},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
BMC Nephrology 2018
Open access · CC-BY
The role of klotho in chronic kidney disease
Springer eBooks 2016
Citation only
Vitamin D and Klotho in Chronic Kidney Disease
Pharmaceutics 2021
Open access · CC-BY
Klotho and Mesenchymal Stem Cells: A Review on Cell and Gene Therapy for Chronic Kidney Disease and Acute Kidney Disease
Transplantation 2022
Citation only
The Value of Klotho in Kidney Transplantation
Nephrology Dialysis Transplantation 2012
Open access · OA
The emerging role of Klotho in clinical nephrology
Springer eBooks 2014
Citation only